Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > PD-1 > EP-130

PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP130-C01High-bind Plate1 plate
EP130-C02Human PD-110 μg
EP130-C03Biotinylated Human PD-L120 μg
EP130-C04Anti-PD-1 Neutralizing Antibody20 μg
EP130-C05Streptavidin-HRP10 μg
EP130-C06Coating Buffer12 mL
EP130-C0710xWashing Buffer 50 mL
EP130-C08Blocking Buffer50 mL
EP130-C09Substrate Solution24 mL
EP130-C10Stop Solution7 mL
  • Background
    Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
  • Application

    The inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L1 to immobilized human PD-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L1 protein, a human PD-1 protein, an anti-PD-1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human PD-1.

    b) Add your molecule of interest to the tests.

    c) Add human PD-L1-Biotin to bind the coated human PD-1.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to PD-1: PD-L1 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to DS document for The assay protocol.

Serial dilutions of Anti-PD-1 Neutralizing antibody (Catalog # EP130-C04) (1:1 serial dilution, from 5μg/mL to 0.02μg/mL) was added into PD-1: Biotinylated PD-L1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:17 Details
  • Number of Drugs in Clinical Trials:141 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message